# Product Snapshot - JPMorgan Funds - Global Healthcare Fund > Audience: country=gb, language=en, role=adv. > Generated: 2026-10-31T15:03:04.392526696Z. ## Identity - **Fund Name**: JPMorgan Funds - Global Healthcare Fund - **Share Class Name**: JPM Global Healthcare C (acc) - USD - **Product Page**: [Product Page](https://am.jpmorgan.com/gb/en/asset-management/adv/products/jpm-global-healthcare-c-acc-usd-lu0432979887) - **ISIN**: LU0432979887 - **Fund Type**: SICAV - **Asset Class**: Equity ## Overview ### Investment objective To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally. ### Registered countries - **Austria**: 10/06/2009 - **Belgium**: 05/04/2018 - **Chile**: 16/11/2018 - **Cyprus**: 05/01/2026 - **Denmark**: 09/10/2014 - **Finland**: 29/05/2009 - **France**: 24/07/2009 - **Germany**: 10/06/2009 - **Greece**: 26/06/2009 - **Hungary**: 21/12/2011 - **Ireland**: 21/05/2009 - **Italy**: 24/07/2009 - **Jersey**: - - **Korea**: 01/02/2017 - **Liechtenstein**: 31/07/2015 - **Luxembourg**: 12/05/2009 - **Netherlands**: 27/05/2009 - **Norway**: 22/06/2009 - **Portugal**: 17/03/2021 - **Spain**: 19/06/2009 - **Sweden**: 16/06/2009 - **Switzerland**: 10/08/2009 - **United Kingdom**: 19/05/2009 [Disclosure 1] ## Fund facts - **Bloomberg**: JPHLUCA LX - **Reuters**: LU0432979887.LUF - **ISIN**: LU0432979887 - **SEDOL**: B554MM7 - **Asset class**: Equity - **Region**: Global - **Fund inception date**: 02/10/2009 - **Share class inception**: 02/10/2009 - **Fund currency**: USD - **Share class currency**: USD - **ESG Approach**: ESG Promote [Disclosure 2] - **SFDR Classification**: Article 8 [Disclosure 3] ## Fund stats - **NAV As of 30/10/2026**: USD 744.97 [Disclosure 4] - **NAV change As of 30/10/2026**: USD 10.03 - **NAV change (%) As of 30/10/2026**: 1.36% - **12 Month NAV high As of 30/10/2026**: USD 744.97 - **12 Month NAV low As of 04/11/2025**: USD 615.06 - **Fund size As of 30/10/2026**: USD 3.51 Bn ## Fees & Charges ### Fees - **Initial charge**: 0.00% - **Redemption charge**: 0.00% - **Ongoing charge**: 1.01% - **Annual management fee (included in ongoing charge)**: 0.80% - **Operating & administrative expenses (included in ongoing charge)**: 0.20% ## Portfolio managers ### Dominic Valder - **Biography**: [Biography](https://am.jpmorgan.com/gb/en/asset-management/adv/bios/dominic-valder/) - **In the industry**: 28 YEARS - **With J.P. Morgan**: 6 YEARS - **Managing this fund**: 4 YEARS ### Bartjan van Hulten - **Biography**: [Biography](https://am.jpmorgan.com/gb/en/asset-management/adv/bios/bartjan-hulten/) - **In the industry**: 30 YEARS - **With J.P. Morgan**: 8 YEARS - **Managing this fund**: 2 YEARS ## Ratings ### Morningstar Summary Rating - **As of **: 30/09/2026 - **Overall**: 4 of 5 stars ## Performance ### Quarterly rolling 12 months _As of 30/09/2026_ | Return | 2021/2022 | 2022/2023 | 2023/2024 | 2024/2025 | 2025/2026 | | --- | ---: | ---: | ---: | ---: | ---: | | JPM C (acc) - USD | -9.70% | 2.51% | 18.53% | -10.13% | 17.25% | | Benchmark | -9.79% | 10.88% | 20.84% | -8.00% | 16.38% | | Excess return (geometric) | 0.10% | -7.55% | -1.91% | -2.31% | 0.75% | ### Calendar year _As of 30/09/2026_ | Return | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | YTD | | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | JPM C (acc) - USD | -14.82% | 20.95% | 3.25% | 22.23% | 24.42% | 11.88% | -8.64% | 3.47% | -1.79% | 15.03% | 3.74% | | Benchmark | -6.81% | 19.80% | 2.51% | 23.24% | 13.52% | 19.80% | -5.41% | 3.76% | 1.13% | 14.83% | 5.23% | | Excess return (geometric) | -8.59% | 0.96% | 0.72% | -0.82% | 9.61% | -6.61% | -3.41% | -0.28% | -2.88% | 0.18% | -1.41% | ### Cumulative _As of 30/09/2026_ | Return | 1 MONTH | 3 MONTHS | 1 YEAR | 3 YEARS | 5 YEARS | 10 YEARS | | --- | ---: | ---: | ---: | ---: | ---: | ---: | | JPM C (acc) - USD | -2.18% | 0.42% | 17.25% | 24.90% | 15.60% | 122.13% | | Benchmark | -1.79% | 3.33% | 16.38% | 29.37% | 29.40% | 133.64% | | Excess return (geometric) | -0.39% | -2.82% | 0.75% | -3.46% | -10.66% | -4.93% | ### Annualised _As of 30/09/2026_ | Return | 3 YEARS | 5 YEARS | 10 YEARS | | --- | ---: | ---: | ---: | | JPM C (acc) - USD | 7.69% | 2.94% | 8.31% | | Benchmark | 8.96% | 5.29% | 8.86% | | Excess return (geometric) | -1.17% | -2.23% | -0.50% | [Disclosure 5] ## Portfolio ### Top holdings _As of 30/09/2026_ | Name | Sector | Weight | | --- | ---: | ---: | | Eli Lilly | Pharmaceuticals | 8.0% | | AbbVie | Biotechnology | 7.3% | | Johnson & Johnson | Pharmaceuticals | 6.3% | | Merck & Co | Pharmaceuticals | 5.3% | | Thermo Fisher Scientific | Life Sciences Tools & Services | 4.6% | | Novartis | Pharmaceuticals | 4.5% | | AstraZeneca | Pharmaceuticals | 4.1% | | UnitedHealth | Health Care Providers & Services | 3.3% | | Abbott Laboratories | Health Care Equipment & Supplies | 2.9% | | Danaher | Life Sciences Tools & Services | 2.9% | ### Sector breakdown _As of 30/09/2026_ | Sector | Fund | Benchmark | Deviation | | --- | ---: | ---: | ---: | | Pharmaceuticals | 41.7% | 46.6% | -4.9% | | Biotechnology | 24.8% | 18.0% | 6.8% | | Health Care Providers & Services | 12.3% | 12.5% | -0.2% | | Life Sciences Tools & Services | 11.6% | 8.5% | 3.1% | | Health Care Equipment & Supplies | 9.5% | 13.8% | -4.3% | | Health Care Technology | 0.0% | 0.6% | -0.6% | | Cash | 0.1% | 0.0% | 0.1% | | Total | 100.0% | 100.0% | 0.0% | ### Regional breakdown _As of 30/09/2026_ | Region | Fund | Benchmark | Deviation | | --- | ---: | ---: | ---: | | North America | 72.9% | 74.1% | -1.2% | | Europe & Middle East ex UK | 18.5% | 16.7% | 1.8% | | United Kingdom | 5.2% | 4.7% | 0.5% | | Japan | 3.0% | 3.4% | -0.4% | | Emerging Markets | 0.3% | 0.0% | 0.3% | | Pacific ex-Japan | 0.0% | 1.1% | -1.1% | | Cash | 0.1% | 0.0% | 0.1% | | Total | 100.0% | 100.0% | 0.0% | ## Documents - [Factsheet](https://jp.techrules.com/rebrandingPDF/LoadPdf.aspx?ShareClassId=224&country=GB&lang=EN¶mMIFID=YES) - [JPMorgan Funds - Global Healthcare Fund - Commentary (A Acc share class)](https://am.jpmorgan.com/content/dam/jpm-am-aem/emea/regional/en/literature/commentary/jpm-global-healthcare-fund-commentary-ce-en.pdf) - [Key Investor Information Document](https://wl.fundsquare.net/serv/down-doc/request?cdClient=jpmorgan&isin=LU0432979887&docTypeCode=KIID&docLang=EN&docCountry=GB) - [JPMorgan Funds - Prospectus](https://am.jpmorgan.com/content/dam/jpm-am-aem/emea/regional/en/regulatory/prospectus/jpmorgan-funds-prospectus-ce-en.pdf) - [JPMorgan Funds - Annual Report](https://am.jpmorgan.com/content/dam/jpm-am-aem/emea/regional/en/regulatory/annual-report/jpmorgan-funds-annual-report-ce-en.pdf) - [JPMorgan Funds - Semi-Annual Report ](https://am.jpmorgan.com/content/dam/jpm-am-aem/emea/regional/en/regulatory/semi-annual-report/jpmorgan-funds-semi-annual-report-ce-en.pdf) ## Disclosures 1. "-" = Registered, but date of registration not known 2. Promotes environmental and / or social characteristics. 3. "Article 8” strategies promote social and/or environmental characteristics, but do not have sustainable investing as a core objective. “Article 9” strategies have a sustainable investment objective. 4. Net Asset Value of a fund’s assets less its liabilities per Share. 5. Past performance is not a guide to current and future performance. The value of your investments and any income from them may fall as well as rise and you may not get back the full amount you invested. Source: J.P. Morgan Asset Management. Share class performance is shown based on the NAV (net asset value) of the share class with income (gross) reinvested including actual ongoing charges excluding any entry and exit fees. The historic performance shown relates to the Share Class ‘JPM Global Healthtech C (acc) – USD’ which was launched on 30/06/00 prior to the merger. This Sub-Fund JPMorgan Funds - Global Healthcare Fund has been launched with the assets of the JPMorgan Investment Funds - Global Healthtech Fund which has been merged into the Sub-Fund on 02/10/09. The historical performance shown corresponds to the historical performance of the former Sub-Fund JPMorgan Investment Funds - Global Healthtech Fund. Benchmark Source: MSCI. Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved, in or related to compiling, computing, or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent. The return of your investment may change as a result of currency fluctuations if your investment is made in a currency other than that used in the past performance calculation. Indices do not include fees or operating expenses and you cannot invest in them. The benchmark is for comparative purposes only unless specifically referenced in the Sub-Funds' Investment Objective and Policy.